Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.

@article{Marchetti2000ManagementOP,
  title={Management of patients with Bacilli Calmette-Gu{\'e}rin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.},
  author={Albert Marchetti and Lei Wang and Raf Magar and Heather Grossman and Donald L. Lamm and Paul F. Schellhammer and Paula L Erwin-Toth},
  journal={Clinical therapeutics},
  year={2000},
  volume={22 4},
  pages={422-38}
}
OBJECTIVE This study was undertaken to identify the expected first- and second-year clinical costs associated with intravesical valrubicin therapy, using a decision analytic model, for patients with Bacilli Calmette-Guérin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder. BACKGROUND Cancer of the urinary bladder is the fourth most common… CONTINUE READING